Belvedere Trading’s Arbutus Biopharma ABUS Stock Holding History

Belvedere Trading’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,200	Closed	-$29.8K	–	730
2025 Q4	$29.8K	Buy	+6,200	New	+$27.9K	﹤0.01%	702

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Belvedere Trading's ABUS Position: Q1 2026 in Review

Belvedere Trading sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 10,721 shares — an estimated $51.6K sold.

Belvedere Trading first reported a position in ABUS in Q3 2021 and held it in 3 quarters. The position peaked at $140K in Q3 2021. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Belvedere Trading reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
Belvedere Trading sold 10,721 Arbutus Biopharma shares in Q1 2026, an estimated $51.6K.
Belvedere Trading first reported a position in Arbutus Biopharma in Q3 2021 and held it in 3 quarters.
Belvedere Trading's Arbutus Biopharma position peaked at $140K in Q3 2021.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Belvedere Trading's 13F filing for Q1 2026, filed 12 May 2026.